MYD88 and neoplasm: Consistently, exogenous dsRNA participates in driving Type I IFN induction via targeting RNA-sensing PRR pathways, including RIG-I/MDA5-IPS-1, TLR7-MyD88 and TLR3-TICAM-1 in dendritic cell subset, so as to evoke and amplify CD8+ T cell anti-tumor immunity (51).